Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3ICH
NCT03243175Phase 3Recruiting
- Sponsor
- CHU de Lille
- Start
- Jan 2019
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in Atrial fibrillation (AFib), intracerebral hemorrhage (ICH), sponsored by CHU de Lille. Started Jan 2019; status: recruiting.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03243175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03243175.